It is worth it to mention that a pathological biomarker cannot always be a therapeutic target; therefore, although BACE1 has the credentials to be a good marker for AD, the efficacy of its inhibition in improving AD clinical features has not been proven. The gene discussed is BACE1; the disease is Alzheimer disease.